Clinical Trials Logo
  1. Home
  2. Cancer of Colon
  3. NCT03524820

Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

Cancer of Colon Clinical Trial

Official title:
Cetuximab Monotherapy or Cetuximab + Chemotherapy for Third Line Rechallenge in Metastatic Colorectal Cancer, RAS+ (RAt Sarcoma Gene) Wild Type Patients, Who Were Treated With Cetuximab Chemotherapy as First Line Treatment

Clinical Trial Summary

This research is intended to check the benefit of treatment with cetuximab in metastatic colorectal cancer patients with wild type RAS as third line treatment. The advantage to the patients is unclear. This study will look if mutations in patients' blood area predictive marker for progression free time (FPT) in metastatic colorectal cancer patients treated with third line cetuximab. A predictive marker for FPT metastatic colorectal cancer patients treated with third line cetuximab will enable a reduction in the number of treated patients. Treatment only of patients with a positive marker is expected to prevent inefficient treatment which will reduce suffering for the patients and reduce unnecessary medical treatment.

Clinical Trial Description

This research is intended to check the benefit of treatment with cetuximab in metastatic colorectal cancer patients with wild type RAS as third line treatment, following first line cetuximab treatment and other second line treatments. The hypothesis is that most cetuximab sensitive cells will be eliminated in the first line of treatment, but may reemerge following other second line treatments which are targeted to other clones in the tumor. The advantage to the patients is unclear, however some preliminary studies show advantage to patients. This study will look if mutations in patients' blood are a predictive marker for progression free time (FPT) in metastatic colorectal cancer patients treated with third line cetuximab. A predictive marker for FPT metastatic colorectal cancer patients treated with third line cetuximab will enable a reduction in the number of treated patients. Treatment only of patients with a positive marker is expected to prevent inefficient treatment which will reduce suffering for the patients and reduce unnecessary medical treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03524820
Study type Interventional
Source Hadassah Medical Organization
Contact
Status Terminated
Phase Phase 2
Start date October 17, 2017
Completion date December 31, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05982184 - Effect of Music Prehabilitation on Preoperative Anxiety Before Surgery N/A
Completed NCT04160650 - Educational Nursing Intervention Among Patients With Colorectal Cancer During Chemotherapy N/A
Recruiting NCT05179824 - Tempus Priority Study: A Pan-tumor Observational Study
Completed NCT04716010 - Developing and Evaluating Product Messaging N/A
Active, not recruiting NCT02458664 - BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer N/A
Completed NCT03246438 - Choice Architecture and Colorectal Cancer Screening Outreach N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Not yet recruiting NCT03910283 - Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer N/A
Completed NCT03928678 - Implementation of Enhanced Recovery After Surgery Program (ERAS) in Colorectal Cancer Surgery, a Randomized Controlled Trial N/A
Completed NCT03546569 - Tumor Cells, Tumor DNA and Immunological Response in Colonic Stent Placement
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Not yet recruiting NCT06035731 - Evaluation of the Medical Service by Socio-aesthetics in Oncology N/A
Completed NCT04971304 - Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars
Completed NCT05030090 - Integrative Nutrition Care Plan for the Patient With Liver and Colorectal Cancer N/A
Not yet recruiting NCT04773626 - Tumor Deposits in Cancer Colon
Recruiting NCT05887531 - Abdominopelvic Cancer Prehabilitation N/A
Withdrawn NCT04274790 - Impact of 5-Fluorouracil (5-FU) on Cancer Cells From Liver Metastases of Colon Cancer
Completed NCT03416777 - Meat-based Versus Pesco-vegetarian Diet and Colorectal Cancer N/A
Completed NCT03210129 - Motivational Interviewing to Increase Physical Activity Behaviour in Cancer Patients N/A
Recruiting NCT00294476 - IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma Phase 2